Reuters logo
BRIEF-FDA staff: Difficult to assess impact of Opana ER’s reformulation on overall abuse of the drug
March 9, 2017 / 2:36 PM / 8 months ago

BRIEF-FDA staff: Difficult to assess impact of Opana ER’s reformulation on overall abuse of the drug

March 9 (Reuters) - Endo International Plc

* FDA staff: postmarketing data suggests opana er reformulation likely reduced nasal abuse rates, but data limitations makes it hard to determine magnitude of effect

* FDA staff: postmarketing data indicate an increase in opana er injection abuse rates over the study period

* FDA staff: the data are difficult to interpret with regard to the impact of opana er’s reformulation on overall abuse of the drug (via any route). Source text for Eikon: (bit.ly/2m62jla) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below